中国医学装备
中國醫學裝備
중국의학장비
CHINA MEDICAL EQUIPMENT
2015年
5期
36-38
,共3页
孔凡霞%陈晓乐%杜秋香%李楠%罗清霞%段红萍%顾海霞
孔凡霞%陳曉樂%杜鞦香%李楠%囉清霞%段紅萍%顧海霞
공범하%진효악%두추향%리남%라청하%단홍평%고해하
重组人血小板生成素%糖皮质激素%环孢素A%免疫性血小板减少性紫癜
重組人血小闆生成素%糖皮質激素%環孢素A%免疫性血小闆減少性紫癜
중조인혈소판생성소%당피질격소%배포소A%면역성혈소판감소성자전
Recombinant human thrombopoietin%Glucocorticoid%Cyclosporine A%Immune thrombocytopenic purpura
目的：探讨重组人血小板生成素、糖皮质激素及环孢素A联合应用治疗免疫性血小板减少性紫癜的疗效。方法：选取75例免疫性血小板减少性紫癜患者，均给予重组人血小板生成素、糖皮质激素及环孢素A治疗，对比治疗前、后血小板(PLT)、白细胞数(WBC)及血红蛋白(Hb)变化情况以及治疗总有效率。结果：治疗前PLT、WBC及Hb分别为(14.41±2.11)×109/L、(8.92±1.01)×109/L及(119.32±9.8)g/L，治疗后分别为(118.92±14.50)×109/L、(9.01±1.05)×109/L及(120.14±6.84)g/L，治疗后血小板数显著高于治疗前，其差异有统计学意义(t=61.769，P＜0.001)。治疗前、后WBC、Hb比较无统计学意义(t=0.535，t=0.594；P＞0.05)。治疗总有效率为89.3%(67/75)，不良反应率为4.0%。结论：联合应用重组人血小板生成素、糖皮质激素及环孢素A治疗ITP的疗效佳，能显著提高血小板数，值得推广。
目的：探討重組人血小闆生成素、糖皮質激素及環孢素A聯閤應用治療免疫性血小闆減少性紫癜的療效。方法：選取75例免疫性血小闆減少性紫癜患者，均給予重組人血小闆生成素、糖皮質激素及環孢素A治療，對比治療前、後血小闆(PLT)、白細胞數(WBC)及血紅蛋白(Hb)變化情況以及治療總有效率。結果：治療前PLT、WBC及Hb分彆為(14.41±2.11)×109/L、(8.92±1.01)×109/L及(119.32±9.8)g/L，治療後分彆為(118.92±14.50)×109/L、(9.01±1.05)×109/L及(120.14±6.84)g/L，治療後血小闆數顯著高于治療前，其差異有統計學意義(t=61.769，P＜0.001)。治療前、後WBC、Hb比較無統計學意義(t=0.535，t=0.594；P＞0.05)。治療總有效率為89.3%(67/75)，不良反應率為4.0%。結論：聯閤應用重組人血小闆生成素、糖皮質激素及環孢素A治療ITP的療效佳，能顯著提高血小闆數，值得推廣。
목적：탐토중조인혈소판생성소、당피질격소급배포소A연합응용치료면역성혈소판감소성자전적료효。방법：선취75례면역성혈소판감소성자전환자，균급여중조인혈소판생성소、당피질격소급배포소A치료，대비치료전、후혈소판(PLT)、백세포수(WBC)급혈홍단백(Hb)변화정황이급치료총유효솔。결과：치료전PLT、WBC급Hb분별위(14.41±2.11)×109/L、(8.92±1.01)×109/L급(119.32±9.8)g/L，치료후분별위(118.92±14.50)×109/L、(9.01±1.05)×109/L급(120.14±6.84)g/L，치료후혈소판수현저고우치료전，기차이유통계학의의(t=61.769，P＜0.001)。치료전、후WBC、Hb비교무통계학의의(t=0.535，t=0.594；P＞0.05)。치료총유효솔위89.3%(67/75)，불량반응솔위4.0%。결론：연합응용중조인혈소판생성소、당피질격소급배포소A치료ITP적료효가，능현저제고혈소판수，치득추엄。
Objective: To investigate the recombinant human thrombopoietin, corticosteroids, cyclosporin A combined therapy to reduce purpura 75 cases of immune thrombocytopenic. Methods: From 2011 March to 2014 January in our hospital were treated with immune thrombocytopenic purpura patients a total of 75 cases, were given the treatment of thrombopoietin, corticosteroids, cyclosporin A recombinant human, compared before and after treatment (platelet), PLT (WBC), WBC (hemoglobin) Hb changes and the total curative effect of therapy. Results:Before treatment, PLT, WBC, Hb were (14.41+2.11)×109/L, (8.92+1.01)×109/L, (119.32+9.8)g/L, respectively after treatment for (118.92+14.50)×109/L, (9.01+1.05)×109/L, (120.14+6.84) g/L, the number of platelet therapy significantly higher than before treatment (t=61.769, P=0.000), WBC, Hb before and after treatment showed no statistical significance (t=0.535, P=0.593;t=0.594, P=0.0553). The total curative effect in the treatment of treatment was 89.3%(67/75), the rate of adverse reaction was 4%. Conclusion:The combined application of recombinant human thrombopoietin, corticosteroids, cyclosporin A in the treatment of ITP curative effect is good, significantly improve the platelet count, worthy of promotion.
